Comparison of seven screening methods in the diagnosis of bladder cancer

( views:61, downloads:0 )
Author:
SUN Yi()
HE Da-lin()
MA Qiang()
WAN Xing-yang()
ZHU Guo-dong()
LI Lei()
LUO Yong()
HE Hui()
YANG Lin()
Journal Title:
CHINESE MEDICAL JOURNAL
Issue:
Volume 119, Issue 21, 2006
DOI:
Key Word:
tumour markers, biological;bladder neoplasms;urine;diagnosis

Abstract´╝Ü Background We compared the validity (evaluated by sensitivity and specificity), reliability (evaluated by reproducibility) and yield (evaluated by predictive value, examining complexity and cost) of individual and combined tests for bladder tumour antigen stat (BTAstat), nuclear matrix protein 22 (NMP22), hyaluronic acid (HA), survivin, CD44v6, vascular endothelial growth factor (VEGF), and voided urine cytology (VUC) in detecting bladder cancer. And at the same time we evaluated the clinical value of these seven detecting methods in the diagnosis of bladder cancer.Methods The six markers and VUC were detected in the urine of cancer group (151 patients with bladder cancer) and two control groups (50 patients with benign urological diseases and 50 healthy controls). The sensitivity, specificity, predictive value, reproducibility, examining complexity and checking cost of each marker and combined markers were calculated.Results There was a significant difference between bladder cancer group and the two control groups. The sensitivity, specificity and positive predictive value were as follows: VUC (36.4%, 100.0%, 100%), BTAstat (76.8%, 87.0%, 89.9%), NMP22 (77.5%, 81.0%, 86.0%), HA (82.8%, 83.0%, 88.0%), survivin (70.2%, 85.0%,87.6%), CD44v6 (50.3%, 79.0%, 78.4%), and VEGF (68.2%, 93.0%, 93.6%). The highest sensitivities were 91.4% for NMP22+BTAstat and HA+NMP22, whereas the combined marker with the lowest sensitivity (62.3%)was VUC+CD44v6. The highest specificity was 93.0% for the combined use of VUC+VEGF and HA+CD44v6 had the lowest specificity (73.0%). The most convenient examining method was the detection for BTAstat, the lowest cost was the detection for HA, and the best reproducibility were the detection for BTAstat and VUC.Conclusions All the markers have obvious clinical value in diagnosis of bladder cancer. The use of BTAstat+HA or NMP22+BTAstat are better examining methods in terms of validity, reliability, and yield.

  • [1]Droller MJ.Bladder cancer:state-of-the-art care.CA Cancer J Clin 1998; 48:269-284.
  • [2]Altman DG,Bland JM.Statistics notes 3:receiver operating characteristic plots.BMJ 1994; 309:188.
  • [3]Li LM.Epidemiology,4th ed.Beijing:People's Medical Publishing House; 1981:55.
  • [4]Lekili M,Sener E,Demir MA,Temeltes G,Muezzinoglu T,Buyuksu C.Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.Urol Res 2004; 32:124-128.
  • [5]Felix MB.Urine cytology.It is still the gold standard for screening? Urol Clin Nort Am 2000; 27:25-37.
  • [6]Schroeder GL,Lorenzo-Gomez MF,Hautmann SH,Friedrich MG,Ekici S,Huland H,et al.A side by side comparison of cytology and biomarkers for bladder cancer detection.J Urol 2004; 172:1123-1126.
  • [7]Pfister C,Chautard D,Devonec M,Perrin P,Chopin D,Rischmann P,et al.Immunocyt test improves the diagnosis accurary of urinary cytology resultat of French multicenter study.J Urol 2003; 169:921-924.
  • [8]Piaton E,Daniel L,Verriele V,Dalifard I,Zimmermann U,Renaudin K,et al.Improved detection of urothelial carcinoma with fluorescence immunocytochemistry(uCyt+assay) and urinary cytology:result of a French Propective Multicenter Study.Lab Invest 2003; 83:845-852.
  • [9]Lokeshwar VB,Schroeder GL,Seizer MG,Hautmann SH,Posey JT,Duncan RC,et al.Bladder tumor markers for monitoring recurrence and screening comparis of hyaluronic acid hyalurinodase and BTAsta tests.Cancer 2002; 95:61-72.
  • [10]Gutierrez Banos JL,del Henar Rebollo Rodrigo M,Antolin Juarez FM,Garcia BM.Usefulness of the BTAstat test for the diagnosis of bladder cancer.Urology 2001; 57:685-689.
  • [11]Giannopoulos A,Manousakas T,Gounari A,Constantinides C,Choremi-Papadopoulou H,Dimopoulos C.Comparative evaluation of the diagnostic performance of the BTAstat test,NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.J Urol 2001; 166:470-475.
  • [12]Grossman HB,Messing E,Soloway M,Tomera K,Katz G,Berger Y,et al.Detection of bladder cancer using a point of care protemic assay.JAMA 2005; 293:810-816.
  • [13]Aguilera Tubet C,Gutierrez Banos JL,Antolin Juarez F,Rebollo Rodrigo MH,Portillo Martin JA,Ruiz Izquierdo F,et al.Comparative study between cystoscopy,urinary cytology,NMP22 and a new method,bladder check,in the follow-up of superficial bladder cell carcinoma.Actas Urol Esp 2005; 29:252-256.
  • [14]Lahme S,Bichler KH,Feil G,Zumbragel A,Gotz T.Comparison of cytology and nuclear matrix protein 22 (NMP22) for the detection and follow-up of bladder cancer.Adv Exp Med Biol 2003; 539:111-119.
  • [15]Menendez V,Filella X,Alcover JA,Molina R,Mallafre JM,Ballesta AM,et al.Usefulness of urinary nuclear matrix protein22 (NMP22) as a marker for transitional cell carcinoma of the bladder.Anticacer Res 2000; 20:1169-1172.
  • [16]Sanchez-Carbayo M,Herrero E,Megias J,Mira A,Soria F.Evaluation of nuclear matrix protein 22 as a tumor marker in the detection of transitional cell carcinoma of the bladder.BJU Int 1999; 84:706-713.
  • [17]Hautmann S,Toma M,Lorenzo Gomez MF,Friedrich MG,Jaekel T,Michl U,et al.Immunocyt and the HA-HAase urine tests for the detection of bladder cancer:a side-by-side comparison.Eur Urol 2004; 46:466-471.
  • [18]Lokeshwar VB,Obek C,Pham HT,Wei D,Young MJ,Duncan RC,et al.Urinary hyaluronis acid and hyaluronidase:markers for bladder cancer detection and evalution of grade.J Urol 2000; 163:348-356.
  • [19]Ho SM,Cheng RY.A promising bladder cancer detection assay:the HA-HAase test.J Urol 2004; 172:824-825.
  • [20]Smith SD,Wheeler MA,Plescia J,Colberg JW,Weiss RM,Altieri DC.Urine detection of survivin and diagnosis of bladder cancer.JAMA 2001; 285:324-328.
  • [21]Sharp JD,Hausladen DA,Maher MG,Wheeler MA,Altieri DC,Weiss RM.Bladder cancer detection with urinary surviving,an inhibitor of apoptosis.Front Biosci 2002; 7:36-41.
  • [22]Shariat SF,Casella R,Khoddami SM,Hernandez G,Sulser T,Gasser TC,et al.Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.J Urol 2004; 171:626-630.
  • [23]Chuang CK,Liao SK.Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinomas.Anticancer Res 2003; 23:4635-4639.
  • [24]Liu Y J,Yan PS,Li J,Jua JF.Expression and significance of CD44s,CD44v6,and nm23 mRNA in human cancer.World J Gastroenterol 2005; 11:6601-6606.
  • [25]Ross JS,del Rosario AD,Bui HX,Kallakury BV,Okby NT,Figge J.Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.Mod Pathol 1998; 9:854-860.
  • [26]Sugino T,Gorham H,Yoshida K,Bolodeoku J,Nargund V,Cranston D,et al.Progressive loss of CD44 gene expression in invasive bladder cancer.Am J Pathol 1996;149:873-882.
  • [27]Toma V,Hauri D,Schmid U,Ackermann D,Maurer R,Alund G,et al.Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma.Am J Pathol 1999; 155:1427-1432.
  • [28]Woodman AC,Goodison S,Drake M,Noble J,Tarin D.Non-invasive diagnosis of bladder carcinoma by enzyme linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia.Clin Cancer Res 2000; 6:2381-2392.
  • [29]Byrne AM,Bouchier-Hayes DJ,Harmey JH.Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).J Cell Mol Med 2005; 9:777-794.
  • [30]Crew JP,O'Brien T,Bradburn M,Fuggle S,Bicknell R,Cranston D,et al.Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.Cancer Res 1997; 57:5281-5285.
  • [31]Sun Y,He H,Ma Q,Wang XY,Yang L,He DL.Clinical evaluation of BTAstat,NMP22,HA,survivin,CD44v6,VEGF and VUC in bladder cancer diagnosis.Natl Med J Chin (Chin) 2005; 85:2507-2512.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn